Maverick Capital Ltd. reduced its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE – Free Report) by 0.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,669,361 shares of the company’s stock after selling 18,718 shares during the period. Maverick Capital Ltd. owned approximately 6.15% of Wave Life Sciences worth $38,270,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Ameritas Investment Partners Inc. grew its holdings in Wave Life Sciences by 50.2% during the first quarter. Ameritas Investment Partners Inc. now owns 7,334 shares of the company’s stock worth $45,000 after acquiring an additional 2,451 shares during the period. Profund Advisors LLC acquired a new position in Wave Life Sciences during the second quarter worth about $53,000. Principal Financial Group Inc. acquired a new position in Wave Life Sciences during the second quarter worth about $74,000. Teacher Retirement System of Texas acquired a new position in Wave Life Sciences during the fourth quarter worth about $86,000. Finally, Hsbc Holdings PLC acquired a new position in Wave Life Sciences during the second quarter worth about $104,000. 89.73% of the stock is owned by institutional investors and hedge funds.
Wave Life Sciences Trading Down 11.0 %
Shares of NASDAQ WVE opened at $8.02 on Friday. Wave Life Sciences Ltd. has a one year low of $3.50 and a one year high of $9.92. The business has a 50-day moving average price of $5.98 and a two-hundred day moving average price of $5.84. The firm has a market capitalization of $982.25 million, a PE ratio of -15.42 and a beta of -1.13.
Analyst Upgrades and Downgrades
A number of research analysts recently issued reports on the company. Mizuho reaffirmed an “outperform” rating and set a $19.00 target price on shares of Wave Life Sciences in a report on Tuesday, June 25th. JPMorgan Chase & Co. started coverage on Wave Life Sciences in a research note on Monday, September 9th. They issued an “overweight” rating and a $10.00 price target on the stock. HC Wainwright lifted their price target on Wave Life Sciences from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, B. Riley started coverage on Wave Life Sciences in a research note on Thursday, September 19th. They issued a “buy” rating and a $11.00 price target on the stock. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $13.38.
View Our Latest Stock Report on Wave Life Sciences
Insider Transactions at Wave Life Sciences
In other Wave Life Sciences news, CEO Paul Bolno sold 48,366 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $5.78, for a total value of $279,555.48. Following the transaction, the chief executive officer now owns 359,059 shares in the company, valued at $2,075,361.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 29.10% of the stock is currently owned by company insiders.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.
Featured Stories
- Five stocks we like better than Wave Life Sciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Top 3 Homebuilder Stocks to Watch as Rates Drop
- What is Insider Trading? What You Can Learn from Insider Trading
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- 3 Tickers Leading a Meme Stock Revival
- KB Home Slips After Earnings: What’s Next for Homebuilders?
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.